Maraviroc

• CAT Number: A000358
• CAS Number: 376348-65-1
• Molecular Formula: C29H41F2N5O
• Molecular Weight: 513.70
• Purity: ≥95%
• Synonyms: Selzentry; 376348-65-1; Celsentri; UK-427857; UK-427,857
• Target: HIV
• Solubility: >25.7mg/mL in DMSO
• Storage: -20°C
• IUPAC Name: 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide
• InChI: InChI=1S/C29H41F2N5O/c1-19(2)27-34-33-20(3)36(27)25-17-23-9-10-24(18-25)35(23)16-13-26(21-7-5-4-6-8-21)32-28(37)22-11-14-29(30,31)15-12-22/h4-8,19,22-26H,9-18H2,1-3H3,(H,32,37)/t23-,24+,25?,26-/m0/s1
• InChIKey: GSNHKUDZZFZSJB-HLMSNRGBSA-N
• SMILES: CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C

Maraviroc（Cat No.:A000358）is an antiretroviral medication used to treat HIV-1 infection. It functions as a CCR5 antagonist, blocking the CCR5 co-receptor on CD4 cells, which prevents the virus from entering and infecting the cells. This unique mechanism makes Maraviroc effective for patients with CCR5-tropic HIV-1 strains, often in combination with other antiretrovirals to enhance treatment efficacy. Maraviroc is well-tolerated, with common side effects including cough, fever, and gastrointestinal disturbances. Its targeted action provides an important option for managing HIV, particularly for patients with drug-resistant virus strains.